VC-backed Verve Therapeutics expands scientific advisory board with new addition
Cambridge, Massachusetts-based Verve Therapeutics, a next-generation cardiovascular company, has named Dr. Andrew Geall to its scientific advisory board. Geall is vice president of formulations, analytics and chemistry at Avidity Biosciences. Verve's backers include GV, ARCH Venture Partners, F-Prime Capital and Biomatics Capital.
16 September 2019•3 mins read
